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What is NSD2?
Histone writers Fig. 1: Amino acids (including K36) on the H3 tail and their modifications4
and erasers add
M = methylation, A = acetylation, P = phosphorylation
and remove histone epigenetic marks that
influence gene expression (Fig. 1). The histone
writer NSD2 is a methyl transferase that adds a
second methyl group onto histone 3 lysine 36
NSD2
(H3K36) (Fig. 1,2).1,7 Other enzymes, such as
(among
NSD1, ASH1L, SETD3, SETMAR, NSD3, and
others)
SMYD2, also promote the di-methylation of
H3K36.7 The H3K36me2 state activates
transcription of various genes associated with
cancer.1 The development and validation of
small molecule inhibitors of NSD2 (NSD2is)
Fig. 2: Histone 3 lysine 36
will provide insight into NSD2’s role in cancer.
mono- to di-methylation7

Drug
• NSD2 inhibitor, IACS 017596-000-3, was
provided as 10 mM stock dissolved in DMSO
Viability Assays
• The Vi-Cell Counter determines the number
of viable cells by counting cells with intact
membranes that uptake Trypan blue (Fig. 3)
• The alamar blue assay detects cellular
metabolic activity by determining the amount
of non-fluorescent resazurin converted into
highly-fluorescent resorufin via cellular
dehydrogenase enzymes (Fig. 4)

How does NSD2 contribute to brain tumors?
In diffuse intrinsic pontine gliomas (DIPG) and pediatric high-grade
gliomas (HGG), a mutation in histone 3 lysine 27 (H3K27) limits
methylation of H3K27 and promotes methylation of its antagonist
H3K36.5,8,9 Increased methylation of H3K36 is accomplished by
increased NSD2 activity. In several DIPG cell lines, knock down of
NSD2 reduced tumorigenesis.8

Objectives
1. Determine if NSD2 inhibitor IACS-17596 affects
proliferation and/or viability of an AML cell line. I
selected an AML cell line called MOLM13, which harbors an
FMS-like tyrosine kinase 3 (FLT3) mutation that is
associated with worse prognosis.
2. Determine if NSD2 inhibitor IACS-17596 would be safe
to use to treat brain tumors by evaluating its affect on
normal brain cells. I selected normal human astrocytes
(NHAs), which are frequently used as a non-transformed
control cell line for brain tumor research.
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Fig. 6: NSD2i Treated & Untreated MOLM13
Cell Counts As Measured by Vi-Cell Counter

Fig. 5: NSD2i Treated & Untreated MOLM13
Cell Viability As Measured by Vi-Cell Counter
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Adding increasing concentrations
of NSD2i caused slower
proliferation on Days 1 – 5
• Surprisingly, adding 0.1 µM or 0.5
µM of NSD2i resulted in greater cell
numbers than the control on Day 8

Adding NSD2i had little to no effect
on cell viability for Days 1 – 4
• Adding 5 µM or 10 µM of NSD2i
decreased cell viability slightly
starting on Day 5/6
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Fig. 7: MOLM13 NSD2i Dose Response Curve as
Determined by Alamar Blue Assays
[measured in Relative Fluorescent Units (RFUs)]

Adding NSD2i concentrations of
up to 10 µM as used in the ViCell experiments shown above
had no effect on RFUs at this
time point (which correlates
with Day 3 of the Vi-Cell
Experiment)
However, adding NSD2i
concentrations above 20 µM
did cause a decrease in RFUs

Experimental Procedures

How does NSD2 contribute to leukemia?
An activating p.E1099K mutation in NSD2 has been identified in
acute lymphoblastic leukemia (ALL).2,3,6 It is more common in
relapsed ALL (6.8%) than in the general ALL population (3%).2 The
mutation is associated with increased cellular proliferation, drug
resistance, and CNS disease.2,3,6 Knock down of NSD2 in several
mutated cell lines decreased cellular proliferation and increased
drug sensitivity.3 The role of NSD2 in other leukemias, such as
acute myeloid leukemia (AML), has not been fully explored.
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Leukemia and brain tumors are the two most common pediatric
cancers. While the survival rate for childhood leukemias is generally
high, some patients become resistant to chemotherapy and
eventually relapse. On the other hand, many children do not survive
a diffuse intrinsic pontine glioma (DIPG) or high-grade glioma
(HGG) diagnosis because there are a limited number of targeted
therapies. Both of these patient populations are in desperate need
of new chemotherapies that are effective and non-toxic.

Cell Lines
• MOLM13 cell line was obtained from
American Type Culture Collection,
Manassas, VA and cultured in RPMI1640
medium with 10% FBS, 1% L-glutamine, &
1% penicillin/streptomycin
• Immortalized NHA cell line was obtained
from Dr. Ken Aldape, Brain Tumor Center,
MD Anderson Cancer Center and cultured in
DMEM/F12 medium with 10% FBS, 1% Lglutamine, & 1% penicillin/streptomycin

Results

RFU (normalized to control)

Why is there a need for new leukemia and brain tumor
treatments?

Methods
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Fig. 8: NHA NSD2i Dose Response Curve as
Determined by Alamar Blue Assays
[measured in Relative Fluorescent Units (RFUs)]
Fig. 3: Beckman Coulter Vi-Cell Experiment
to Measure Cell Counts & Viability
MOLM13 cells (83x104 per well) were plated, and Vi-Cell data was collected
for the next eight days. About one day after plating, 0.1 µM, 0.5 µM, 1 µM, 5
µM, & 10 µM of IACS-17596 was added to all wells besides the control.
About three days later, an additional 4 mL of supplemented RPMI1640 media
was added to each well to sustain cell growth. Three biological replicates
were completed (although not all replicates included a count for each day).

Fig. 4: Alamar Blue Assay to Measure Cell Viability
NHA cells (5x104 per well) and MOLM13 cells (20x104 per well) were
plated. About one day after plating, 0.05% DMSO was added to the control
wells in triplicate and 0.05 µM, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 20 µM,
30 µM, 40 µM, & 50 µM of IACS-17596 was added to the other wells in
triplicate. Next resazurin (alamar blue) was added to the MOLM13 cells one
day later and to the NHAs four days later. Fluorescence was then
measured 16-18 hours later using the CLARIOstar microplate reader. Three
MOLM13 and two NHA biological replicates were completed (although not
all replicates included all concentrations).
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Adding NSD2i concentrations of up
to 20 µM had no affect on the
viability of the NHAs (as measured
by RFUs)
Adding NSD2i concentrations
above 20 µM caused a decrease in
viability of the NHAs (as measured
by RFUs)

Conclusions
1. During the first few days after adding the NSD2 inhibitor IACS17596, MOLM13 proliferation was slowed but viability was not
affected. However, higher concentrations like 5 µM or 10 µM
did eventually cause a decrease in viability, but this may have
been due to non-specific effects of the drug.
2. The NSD2 inhibitor IACS-17596 did not reduce viability of the
NHAs for concentrations of up to 20 µM, which shows promise
for low toxicity on normal astrocytes.

Future Work
• Perform Western Blots comparing controls with samples treated
with NSD2 knockdown constructs or a NSD2 inhibitor to validate
that K36 methylation is reduced by the inhibitor and the observed
decrease in cell proliferation/viability is due solely to specific
effects of the drug
• Conduct gene analysis in the presence of NSD2 knockdown
constructs and a NSD2 inhibitor to determine which cancer-related
genes are up-regulated or down-regulated by NSD2
• Test IACS-17596 on pediatric brain cancers, such as DIPG, using
concentrations that do not affect viability of NHAs

